Rural Pharmacy and Prescription Drugs – News
News stories from the past 60 days.
DEA: Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017
Federal Register
Apr 1, 2026 - Notice from the Drug Enforcement Administration (DEA) making technical corrections to the February 5, 2026, final rule.
Source: Federal Register
Mar 15, 2026 - Discusses pharmacist-led point-of-care testing as a strategy to increase access to acute care in rural areas. Notes challenges in advancing that strategy including insurance reimbursement and regulations.
Source: Drug Topics
Feb 26, 2026 - Notice from the Health Resources and Services Administration (HRSA) seeking comments on a proposed information collection request titled "340B Rebate Model Pilot Program Application, Implementation, and Evaluation, OMB No. 0906-XXXX." This information collection request includes the collection of proposed rebate model plans from qualifying drug manufacturers, the ongoing collection of sales data from drug manufacturers for program evaluation and 340B Program integrity and compliance monitoring, and the collection of data submitted by covered entities to manufacturers to request a rebate in connection with a potential 340B Rebate Model Pilot Program. Comments are due by April 27, 2026.
Source: Federal Register
Feb 26, 2026 - The Health Resources and Services Administration (HRSA) is allowing an additional 30 days for comments on the February 17, 2026, request for information regarding the potential use of rebates to effectuate the ceiling price under the 340B Program. Comments are now due by April 20, 2026.
Source: Federal Register
HRSA: Request for Information: 340B Rebate Model Pilot Program
Federal Register
Feb 17, 2026 - The Health Resources and Services Administration (HRSA) is seeking comments on a request for information (RFI) regarding the potential use of rebates to effectuate the ceiling price under the 340B Program. The information collected through this RFI will be used to evaluate the potential benefits and costs of a rebate model, and such a model's operational, financial, and access to drugs for patients of a rebate model on covered entities, manufacturers, and other stakeholders. Comments are due by March 19, 2026.
Source: Federal Register